Firefly Neuroscience Partners with Neurology Consultants for Patient Care
![Firefly Neuroscience Partners with Neurology Consultants for Patient Care](https://investorshangout.com/images/blog/investors-hangout-newswire.jpg)
Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants
Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) technology company developing innovative neuroscientific solutions that improve brain health outcomes for patients with mental illnesses and neurological disorders, today announced that it has formed a strategic partnership with Neurology Consultants of Dallas (“NCD”) to help enhance early detection efforts and disease management for patients suffering from cognitive decline. NCD will incorporate Firefly’s Brain Network Analytics (“BNA”) technology into its patient workflow and conduct clinical studies aimed at identifying biomarkers for predicting the onset of dementia that can potentially optimize patient care pathways.
Collaboration Goals
NCD has been at the forefront of neurological care since the 1970s, providing inpatient and outpatient services. Its expertise and dedication to improving patient outcomes make NCD an ideal partner for Firefly,” said Jon Olsen, Firefly’s CEO. "We look forward to updating our BNA technology with real patient use cases and feedback to better serve those suffering from cognitive decline and other neurological disorders across the U.S."
Benefits of BNA Technology Integration
Dr. Puneet Gupta, NCD's VP Health Innovation Strategy and Ventures stated, "Our integration of Firefly's BNA technology highlights the clinical value of the platform, providing diagnostic insights and trending analysis of cognitive health in conditions such as Alzheimer's disease, Parkinson’s disease, epilepsy, multiple sclerosis, concussions, and general aging. Incorporating BNA into our serial cognitive exams allows for a more comprehensive understanding of patients' brain function and cognitive health over time."
Enhancing Patient Care
By establishing a baseline for every patient, healthcare providers can more accurately track cognitive changes, promoting early detection and effective management of cognitive decline. The integration of BNA technology is expected to enhance neurology testing for millions of patients in the U.S. by encouraging widespread adoption of advanced diagnostic tools.
Commitment to Patient Outcomes
Dr. Anna Tseng, NCD’s Chief Development Officer, mentioned, “Recently, NCD was selected to participate in the Centers for Medicare and Medicaid Services’ GUIDE Model, which aims to significantly improve quality of life for people with dementia. We believe that our partnership with Firefly will enhance our ability to stage the level of cognitive impairment in patients participating in the program, and thereby manage their care accordingly by the stage of dementia. This aligns with our ongoing commitment to advancing patient care through innovative technology.”
About Firefly Neuroscience
Firefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) technology company developing innovative neuroscientific solutions that improve brain health outcomes for patients with mental illnesses and neurological disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA) platform revolutionizes diagnostic and treatment methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD.
Investment and Development
Over the past 15 years, Firefly has invested approximately $60 million in developing its BNA platform, building a comprehensive database of brain wave tests, securing patent protection, and achieving FDA approval. The Company is now launching the BNA platform commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.
State-of-the-Art Technology
The BNA platform is a software as a medical solution (SAMS) that was developed using artificial intelligence and machine learning on Firefly’s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients. The BNA platform, alongside an FDA-cleared EEG system, provides clinicians with comprehensive insights into brain function and cognition, thereby enhancing the ability to accurately diagnose mental illnesses and cognitive disorders.
About Neurology Consultants of Dallas
Neurology Consultants of Dallas (NCD) is a distinguished physician-owned and physician-led practice dedicated to providing exceptional neurological care to the community. With a focus on treating the whole person, NCD offers leading-edge services for both adult and pediatric patients, inpatient and outpatient.
Commitment to Excellence
NCD's comprehensive services include expertise across specialties, advanced diagnostics and imaging, clinical research, and neurorehabilitation. They actively collaborate with startups and established healthcare companies to refine products, shape future therapies, and optimize workflows, driving innovation that impacts healthcare on a broader scale.
Frequently Asked Questions
What is the purpose of the partnership between Firefly and NCD?
The partnership aims to enhance early detection and disease management for patients suffering from cognitive decline using Firefly's BNA technology.
How does BNA technology benefit patients?
BNA technology facilitates the identification of biomarkers, allowing for better tracking and management of cognitive decline over time.
What are the main conditions that BNA technology addresses?
BNA technology addresses conditions such as Alzheimer's disease, Parkinson’s disease, epilepsy, multiple sclerosis, concussions, and age-related cognitive decline.
How long has Firefly been developing its BNA technology?
Firefly has invested approximately $60 million in developing its BNA platform over the past 15 years.
What is NCD’s approach to patient care?
NCD focuses on treating the whole person by combining the latest research and technology with compassionate, individualized care.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- AEG and Onex Partners Complete Sale of ASM Global to Legends
- Bright Green Partners with Benuvia for Raw Material Supply
- Growth Insights for Global Pharma Grade Plastic Packaging Market
- High-Performance Computing Market Growth to USD 92.33 Billion
- Cancer Vaccines Market Growth Forecast and Insights
- Performance Coatings Market Growth Opportunities
- Industrial Robotics Market Growth Projections for 2032
- Significant Growth Ahead for Blood Culture Tests Market
- CytoDyn Partners with CRO for Phase II Inflammation Study
- Exclusive Livestream Skincare Event on TikTok by VERB